AC
MDGL icon

Armistice Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Armistice Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-320,000
Closed -$73.9M – 267
2023
Q2 		$73.9M Buy
+320,000
New +$86.7M 1.07% 14

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital's MDGL Position: Q1 2026 in Review

Armistice Capital reduced its Madrigal Pharmaceuticals (MDGL) stake by 0.42% in Q1 2026, selling an estimated $536K and leaving 264,583 shares worth $139M. The position accounts for 2.46% of the portfolio, ranked #5.

Armistice Capital first reported a position in MDGL in Q1 2015 and has held it in 40 quarters since. The position peaked at $155M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Armistice Capital held 264,583 shares of Madrigal Pharmaceuticals worth $139M as of Q1 2026.
  • Armistice Capital sold 1,122 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $536K.
  • Madrigal Pharmaceuticals made up 2.46% of Armistice Capital's portfolio in Q1 2026, its #5 holding.
  • Armistice Capital first reported a position in Madrigal Pharmaceuticals in Q1 2015 and has held it in 40 quarters since.
  • Armistice Capital's Madrigal Pharmaceuticals position peaked at $155M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.